Literature DB >> 3208445

Neutralizing antibodies in relation to antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus type I.

B Böttiger1, K Ljunggren, A Karlsson, K Krohn, E M Fenyö, M Jondal, G Biberfeld.   

Abstract

The presence of neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) was investigated in sera from 73 HIV-1 seropositive subjects at different clinical stages. Virus neutralization was measured as survival of MT-4 cells in a 6-7 day microassay. Sixty-three sera were also tested for antibodies inducing virus-specific antibody-dependent cellular cytotoxicity (ADCC). Neutralizing antibodies were found in 59% of sera tested, the positivity rate being 50% (9/17) in asymptomatic subjects, 67% (12/18) in patients with persistent generalized lymphadenopathy (PGL) and 54% (14/26) in AIDS patients (not significant differences). ADCC antibodies were present in 43% of the sera. Neutralizing antibodies and ADCC-inducing antibodies were found simultaneously in 35% (22/63) of the sera. Neutralizing antibodies alone were found in 22% (14/63) and ADCC antibodies alone in 6% (4/63) of the sera tested. Thirty-seven per cent (23/63) of the sera were negative for both types of antibodies, 62% of the sera with neutralizing antibodies also had ADCC inducing antibodies and 85% of the sera with ADCC antibodies had neutralizing antibodies. The titres of ADCC antibodies were higher than those of neutralizing antibodies. Thus, the presence of ADCC antibodies was related to the presence of neutralizing antibodies, but no correlation was found between the titres of these antibodies in sera positive for both activities.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3208445      PMCID: PMC1541774     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein.

Authors:  L A Lasky; J E Groopman; C W Fennie; P M Benz; D J Capon; D J Dowbenko; G R Nakamura; W M Nunes; M E Renz; P W Berman
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

2.  Detection of antibodies which mediate human immunodeficiency virus-specific cellular cytotoxicity (ADCC) in vitro.

Authors:  K Ljunggren; E M Fenyö; G Biberfeld; M Jondal
Journal:  J Immunol Methods       Date:  1987-11-23       Impact factor: 2.303

3.  Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus.

Authors:  A M Prince; D Pascual; L B Kosolapov; D Kurokawa; L Baker; P Rubinstein
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

4.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

5.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

6.  Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages.

Authors:  K Ljunggren; B Böttiger; G Biberfeld; A Karlson; E M Fenyö; M Jondal
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

7.  Characterization and differentiation of CD4-, CD8- thymocytes sorted with the Ly-24 marker.

Authors:  W C Gause; J D Mountz; A D Steinberg
Journal:  J Immunol       Date:  1988-01-01       Impact factor: 5.422

8.  Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

Authors:  D D Ho; M G Sarngadharan; M S Hirsch; R T Schooley; T R Rota; R C Kennedy; T C Chanh; V L Sato
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

9.  Variable and conserved neutralization antigens of human immunodeficiency virus.

Authors:  R A Weiss; P R Clapham; J N Weber; A G Dalgleish; L A Lasky; P W Berman
Journal:  Nature       Date:  1986 Dec 11-17       Impact factor: 49.962

10.  HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.

Authors:  S D Putney; T J Matthews; W G Robey; D L Lynn; M Robert-Guroff; W T Mueller; A J Langlois; J Ghrayeb; S R Petteway; K J Weinhold
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

View more
  8 in total

Review 1.  The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.

Authors:  C Farquhar; G John-Stewart
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

2.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection.

Authors:  U Ziegner; D Campbell; K Weinhold; I Frank; R Rutstein; S E Starr
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 4.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

5.  Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies.

Authors:  P A Broliden; B Mäkitalo; L Akerblom; J Rosen; K Broliden; G Utter; M Jondal; E Norrby; B Wahren
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

6.  Antibody-dependent cellular cytotoxicity detects type- and strain-specific antigens among human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus SIVmac isolates.

Authors:  K Ljunggren; G Biberfeld; M Jondal; E M Fenyö
Journal:  J Virol       Date:  1989-08       Impact factor: 5.103

7.  A dimeric form of the HIV-1 antibody 2G12 elicits potent antibody-dependent cellular cytotoxicity.

Authors:  Joshua S Klein; Alexandre Webster; Priyanthi N P Gnanapragasam; Rachel P Galimidi; Pamela J Bjorkman
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

8.  HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads.

Authors:  Jennifer Mabuka; Ruth Nduati; Katherine Odem-Davis; Dylan Peterson; Julie Overbaugh
Journal:  PLoS Pathog       Date:  2012-06-14       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.